March 19 (Reuters) - Novo Nordisk said on Thursday the U.S. Food and Drug Administration has approved a higher dose of its ...

Revolutionary GLP-1 medications like Ozempic and Wegovy can help people who have struggled with weight drop pounds far more ...

California says it leads with science and compassion. By cutting treatment for chronic obesity, it is doing the opposite. If ...

As use of GLP-1 medications surges, tools like Weight Loss Buddy emerge as critical infrastructure for sustaining ...

A science-based weight loss protocol designed to help men lose fat, preserve muscle, and improve metabolic health ...

The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

How the rush to release affordable and accessible versions of weight loss drugs could reshape the fight against ‘diabesity’ ...

Being overweight or obese is associated with numerous health problems and about 75% of American adults are overweight or obese. An Adult with a body mass index (BMI) of 30 ...

The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and long-term weight-loss maintenance. The higher dose, 7.2 mg, produced an ...

Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users lose more weight and keep it off.

California is denying popular and effective weight loss drugs to poor people — likely to spite President Donald Trump, who has tried to make them cheaper. As a result, only those who can afford to pay ...

Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for chronic weight ...